Tolerogenic vaccination with MOG/VitD overcomes aggravating effect of C. albicans in experimental encephalomyelitis
ARTIGO
Inglês
Multiple sclerosis (MS) is an immune‐mediated demyelinating disorder of the central nervous system (CNS). We described that Candida albicans (Ca) aggravates experimental autoimmune encephalomyelitis (EAE) that is a model to study MS. We also observed that vaccination with a myelin peptide (MOG) in...
Multiple sclerosis (MS) is an immune‐mediated demyelinating disorder of the central nervous system (CNS). We described that Candida albicans (Ca) aggravates experimental autoimmune encephalomyelitis (EAE) that is a model to study MS. We also observed that vaccination with a myelin peptide (MOG) in the presence of vitamin D (VitD) protected mice against EAE. In this work, we investigated whether Ca infection interferes with the efficacy of this vaccine. EAE was induced in C57BL/6 female mice previously vaccinated with MOG+VitD and then infected 3 days before encephalomyelitis induction. Vaccination was able to control EAE development in infected mice. These animals gained weight, and only a few progressed to very low clinical scores. Protection was confirmed by a lower inflammatory infiltration in the CNS and was also associated with a reduced production of encephalitogenic cytokines by spleen and CNS cell cultures. The elevated percentage of CD25+FoxP3+ cells suggests that regulatory T cells are involved in the protection. Adoptive transfer of splenocytes from mice vaccinated with MOG+VitD supports the view that protection is mediated by immunoregulatory cells. Together, these experiments provide evidence demonstrating that EAE can be prevented by the inverse vaccination with MOG+VitD even in the presence of a disease‐aggravating infectious agent
FUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULO - FAPESP
2012/12540-7; 2013/14353-2
Fechado
Tolerogenic vaccination with MOG/VitD overcomes aggravating effect of C. albicans in experimental encephalomyelitis
Tolerogenic vaccination with MOG/VitD overcomes aggravating effect of C. albicans in experimental encephalomyelitis
Fontes
CNS neuroscience & therapeutics Vol. 22, no. 10 (Oct., 2016), p. 807-816 |